AU8738401A - Novel kallikrein gene - Google Patents

Novel kallikrein gene

Info

Publication number
AU8738401A
AU8738401A AU8738401A AU8738401A AU8738401A AU 8738401 A AU8738401 A AU 8738401A AU 8738401 A AU8738401 A AU 8738401A AU 8738401 A AU8738401 A AU 8738401A AU 8738401 A AU8738401 A AU 8738401A
Authority
AU
Australia
Prior art keywords
kallikrein gene
novel
novel kallikrein
gene
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU8738401A
Other languages
English (en)
Inventor
George M Yousef
Eleftherios P Diamandis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mt Sinai Hospital
Original Assignee
Mt Sinai Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mt Sinai Hospital filed Critical Mt Sinai Hospital
Publication of AU8738401A publication Critical patent/AU8738401A/xx
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21034—Plasma kallikrein (3.4.21.34)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU8738401A 2000-08-11 2001-08-10 Novel kallikrein gene Pending AU8738401A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22485300P 2000-08-11 2000-08-11
PCT/CA2001/001141 WO2002014485A2 (en) 2000-08-11 2001-08-10 Kallikrein gene

Publications (1)

Publication Number Publication Date
AU8738401A true AU8738401A (en) 2002-02-25

Family

ID=22842508

Family Applications (2)

Application Number Title Priority Date Filing Date
AU8738401A Pending AU8738401A (en) 2000-08-11 2001-08-10 Novel kallikrein gene
AU2001287384A Ceased AU2001287384B2 (en) 2000-08-11 2001-08-10 Kallikrein gene

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001287384A Ceased AU2001287384B2 (en) 2000-08-11 2001-08-10 Kallikrein gene

Country Status (9)

Country Link
US (2) US7199229B2 (https=)
EP (1) EP1309703B1 (https=)
JP (1) JP2004505649A (https=)
AT (1) ATE330017T1 (https=)
AU (2) AU8738401A (https=)
CA (1) CA2418422C (https=)
DE (1) DE60120712T2 (https=)
ES (1) ES2266245T3 (https=)
WO (1) WO2002014485A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022497B1 (en) * 1999-03-11 2006-04-04 Mt. Sinai Hospital Human kallikrein-like genes
US9012141B2 (en) * 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
WO2002014485A2 (en) 2000-08-11 2002-02-21 Mount Sinai Hospital Kallikrein gene
ATE365922T1 (de) * 2000-10-27 2007-07-15 Mount Sinai Hospital Corp Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
JP2004512540A (ja) 2000-11-01 2004-04-22 マウント・サイナイ・ホスピタル 卵巣癌の検出
US20040203012A1 (en) * 2001-05-25 2004-10-14 Eleftherios Diamandis Method of detecting and monitoring prostate and ovarian cancers
CA2463920A1 (en) * 2001-10-16 2003-04-24 Mount Sinai Hospital Methods for detecting ovarian cancer
AU2003269618A1 (en) * 2002-08-28 2004-03-19 Mount Sinai Hospital Methods for detecting breast and ovarian cancer
CA2497061A1 (en) * 2002-08-28 2004-03-11 Mount Sinai Hospital Methods for detecting endocrine cancer using kallikrein 13 (klk13) as a biomarker
EP1546728A2 (en) * 2002-09-26 2005-06-29 Mount Sinai Hospital Methods for detecting endocrine cancer
CA2516591A1 (en) * 2003-02-26 2004-09-10 Mount Sinai Hospital Multiple marker assay for detection of ovarian cancer
WO2004077060A2 (en) * 2003-02-27 2004-09-10 Mount Sinai Hospital Assay for detection of renal cell carcinoma
CA2468651A1 (en) * 2003-06-13 2004-12-13 Eleftherios P. Diamandis Detection of neurodegenerative diseases
US20060269971A1 (en) * 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer
EP1711616A1 (en) * 2004-01-28 2006-10-18 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with kallikrein 15 (klk15)
US20110129499A1 (en) 2008-05-19 2011-06-02 Paulo Maciag Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
US9226958B2 (en) 2010-10-01 2016-01-05 University Of Georgia Research Foundation, Inc. Use of Listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
AU2012229218B2 (en) 2011-03-11 2017-03-02 Advaxis, Inc. Listeria-based adjuvants
CN104411327A (zh) 2012-03-12 2015-03-11 阿德瓦希斯公司 李斯特菌疫苗治疗以后的抑制细胞功能抑制
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022497B1 (en) 1999-03-11 2006-04-04 Mt. Sinai Hospital Human kallikrein-like genes
US20020064856A1 (en) * 2000-06-26 2002-05-30 Gregory Plowman Novel proteases
JP2004515220A (ja) * 2000-07-21 2004-05-27 インサイト・ゲノミックス・インコーポレイテッド プロテアーゼ
WO2002014485A2 (en) 2000-08-11 2002-02-21 Mount Sinai Hospital Kallikrein gene
CA2360219A1 (en) 2000-10-27 2002-04-27 Mount Sinai Hospital Method for detecting alzheimer's disease
ATE365922T1 (de) * 2000-10-27 2007-07-15 Mount Sinai Hospital Corp Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
JP2004512540A (ja) * 2000-11-01 2004-04-22 マウント・サイナイ・ホスピタル 卵巣癌の検出
US20040203012A1 (en) * 2001-05-25 2004-10-14 Eleftherios Diamandis Method of detecting and monitoring prostate and ovarian cancers
CA2463920A1 (en) * 2001-10-16 2003-04-24 Mount Sinai Hospital Methods for detecting ovarian cancer
US20050287528A1 (en) 2002-04-04 2005-12-29 Mount Sinai Hospital Methods for detecting ovarian cancer
CA2497061A1 (en) 2002-08-28 2004-03-11 Mount Sinai Hospital Methods for detecting endocrine cancer using kallikrein 13 (klk13) as a biomarker
AU2003269618A1 (en) 2002-08-28 2004-03-19 Mount Sinai Hospital Methods for detecting breast and ovarian cancer
EP1546728A2 (en) 2002-09-26 2005-06-29 Mount Sinai Hospital Methods for detecting endocrine cancer
CA2516591A1 (en) 2003-02-26 2004-09-10 Mount Sinai Hospital Multiple marker assay for detection of ovarian cancer
WO2004077060A2 (en) 2003-02-27 2004-09-10 Mount Sinai Hospital Assay for detection of renal cell carcinoma
CA2468651A1 (en) 2003-06-13 2004-12-13 Eleftherios P. Diamandis Detection of neurodegenerative diseases
US20060269971A1 (en) 2003-09-26 2006-11-30 Mount Sinai Hospital Methods for detecting prostate cancer

Also Published As

Publication number Publication date
CA2418422A1 (en) 2002-02-21
AU2001287384B2 (en) 2007-03-29
JP2004505649A (ja) 2004-02-26
WO2002014485A2 (en) 2002-02-21
US7507403B2 (en) 2009-03-24
EP1309703A2 (en) 2003-05-14
US20040058342A1 (en) 2004-03-25
ATE330017T1 (de) 2006-07-15
DE60120712D1 (en) 2006-07-27
CA2418422C (en) 2011-06-07
DE60120712T2 (de) 2007-07-19
WO2002014485A3 (en) 2003-01-09
ES2266245T3 (es) 2007-03-01
US20070178114A1 (en) 2007-08-02
US7199229B2 (en) 2007-04-03
EP1309703B1 (en) 2006-06-14

Similar Documents

Publication Publication Date Title
AU8738401A (en) Novel kallikrein gene
YU68002A (sh) Modifikovani faktor viii
BR0209242A (pt) Aminopolidiorganossiloxanos amido-funcionais
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
MXPA03005960A (es) Nuevas mezclas de enzimas microbianas.
MXPA03008961A (es) Composicion de vacuna.
TR200202194T2 (tr) Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
ZA200205479B (en) Novel biarylcarboxamides.
EG24742A (en) Vaccine composition.
AU144678S (en) Bottle
MXPA03003375A (es) Compresor lineal.
BR0110375B1 (pt) compressor.
MXPA03009698A (es) Vacuna multivalente que comprende un antigeno vih y un antigeno vsh y/o un antigeno vph.
ZA200302929B (en) Compositions comprising cyclohexamantane.
MXPA03007693A (es) Composicion para la piel.
MXPA03008164A (es) Agentes anti-epileptogenos.
HUP0400438A3 (en) Broadspectrum 2-amino-benzoxazole-6-sulfonamides, their use as hiv protease inhibitor and pharmaceutical compositions containing them
AU2001269575A1 (en) Nucleic acid sequences and proteins involved in cellular senescence
MXPA03001991A (es) Novedosas arilalcano-sulfonamidas.
EG23378A (en) Composition.
MXPA03000512A (es) Oxiguanidina-pirazinonas ciclicas como inhibidores de proteasas.
MXPA03001783A (es) N-(3,5-dicloro-2-metoxifenil)-4-metoxi-3- piperazin-1 -il -bencenosulfonamida.
ZA200403323B (en) Anthelmintic composition.
MXPA01000464A (es) Composicion.
MXPA03004166A (es) Nuevos usos de combinaciones de agonistas de 5-ht1a e inhibidores de la recaptacion de serotonina.